Intermediate-risk thyroid carcinoma: indicators of a poor prognosis
Arch. endocrinol. metab. (Online)
; 64(6): 764-771, Nov.-Dec. 2020. tab
Article
в En
| LILACS
| ID: biblio-1142213
Ответственная библиотека:
BR1.1
ABSTRACT
ABSTRACT Objective:
The intermediate-risk (IR) category includes tumors with different degrees of aggression. We aimed to identify the risk factors associated with unfavorable response to initial treatment and compare the effect of low/high radioactive iodine (RAI) therapy. Subjects andmethods:
A total of 614 IR patients were selected from a database, during 1972-2015. All patients underwent total thyroidectomy and RAI therapy and were reclassified after 12-18 months into the favorable (complete/indeterminate) response group and the unfavorable (biochemical/incomplete structural) response group. A total of 92 patients were assessed for late response (mean 9.19 ± 5.73 years). Age, gender, tumor size, histology, multifocality, vascular invasion, extrathyroidal extension, presence and number of lymph node metastasis, and stimulated thyroglobulin at ablation (sTg) were evaluated.Results:
Mean age at diagnosis was 41.47 ± 15.81 years, and 83.6% of the patients were female. Within 12-18 months after initial therapy, unfavorable response was detected in 41.2% of the patients and was associated, in multivariate analysis, with lymph node metastasis (p = 0.041; odds ratio [OR] = 1.9), presence of more than five metastatic lymph nodes (p = 0,017; OR = 2.6), and sTg > 10 ng/mL (p = 0.005; OR = 10.0). For patients with a longer follow-up, sTg >10 ng/mL was associated with unfavorable response (p = 0.002; OR = 6.8). A higher RAI dose was not related to better prognosis at the end of the follow-up.Conclusion:
A sTg level of >10 ng/mL and lymph node metastasis were associated with an unfavorable response 12-18 months after initial treatment. A RAI dose below 150 mCi was proven sufficient to treat IR patients.Key words
Полный текст:
1
База данных:
LILACS
Основная тема:
Thyroid Neoplasms
/
Iodine Radioisotopes
Тип исследования:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Пределы темы:
Female
/
Humans
/
Male
Язык:
En
Журнал:
Arch. endocrinol. metab. (Online)
Тематика журнала:
ENDOCRINOLOGIA
/
METABOLISMO
Год:
2020
Тип:
Article